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Background: Risk factors for venous thromboembolism (VTE) of total joint arthroplasty (TJA) have been examined by
many studies. A comprehensive systematic review of recent findings of high evidence level in this topic is needed.
Methods: We conducted a PubMed search for papers published between 2003 and 2013 that provided level-I and
level-II evidences on risk factors for VTE of TJA. For each potential factors examined in at least three papers, we
summarize the the number of the papers and confirmed the direction of statistically significant associations, e.g.
“risk factor” “protective factor” or “controversial factor”.
Results: Fifty-four papers were included in the systematic review. Risk factors found to be associated with VTE of
both total hip arthroplasty and total knee arthroplasty included older age, female sex, higher BMI, bilateral surgery,
surgery time > 2 hours. VTE history was found as a VTE risk factor of THA but an controversial factor of TKA. Cemented
fixation as compared to cementless fixation was found as a risk factor for VTE only of TKA. TKA surgery itself was
confirmed as a VTE risk factor compared with THA surgery.
Conclusions: This systematic review of high level evidences published in recent ten years identified a range of
potential factors associated with VTE risk of total joint arthroplasty. These results can provide informations in this topic
for doctors, patients and researchers.
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Venous thrombpembolism (VTE) remains a problem in
patients after undergoing the total joint arthroplasty
(TJA), which includes total hip arthroplasty (THA) and
total knee arthroplasty (TKA) [1-4]. Among in-hospital
patients who received recommended VTE prophylaxis,
symptomatic deep vein thrombosis (DVT) rates were
0.26%-0.63% and rates for pulmonary embolism (PE)
were 0.14%-0.27% after total joint arthroplasty, reported
by a systematic review [5]. Patients are suffering from
10 times of healthcare costs and more than twice of length
staying in hospital compared with those without VTE, and
the mortality rate associated with pulmonary embolism
(PE) is reported to be 19.49% [6]. In consideration of the* Correspondence: shenbin71@hotmail.com
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unless otherwise stated.large number of TJA patients worldwide, VTE remains
threatening.
Close monitoring regime and appropriate thrombopro-
phylaxis are in urgent need to minimize the rate of VTE,
which should be based on VTE risk stratification. Identify-
ing VTE risk factors is crucial and challenging because
there are a number of potential VTE risk factors being
worthy of note. Several individual studies [7] focusing on
specific risk factors such as previous thrombosis, malig-
nancy and so forth represent a potential wealth of evi-
dence regarding a range of VTE risk factors after TJA.
A table of “commonly cited risk factors” for VTE after
total joint arthroplasty provided by AAOS [8] can be
applied to clinical practice in risk identifying. However,
there have been no efforts to aggregate existing reser-
voir of evidence of a more comprehensive set of risk
factors, to our knowledge.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Exclusion criteria
Exclusion criteria Example or explanation
No living human subjects e.g. mice model
Focus on wrong procedure e.g. unicompartmental knee replace-ment





e.g. bleeding or blood transfusion
Focus on fat embolism e.g. fat embolism after femoral head
resection
Zhang et al. BMC Musculoskeletal Disorders  (2015) 16:24 Page 2 of 14To summarize the published literature on risk factors
for VTE of TJA relating to patient demographic and
clinical factors, laboratory indexes, health care provider
characteristics and thromboprophylaxes, we conducted
this systematic review of high level studies [9] in recent
ten years (2003–2013). This effort may be helpful to im-
prove our knowledge and therefore promote a new VTE
risk assessment system for patients undergoing total
joint arthroplasty and doctors paying attention to this
issue.Have not mentioned any
risk factor
e.g. prevelance studied alone
Not primary clinical research e.g. literature review or guidline
Level III prognostic study e.g. case–control
Level IV prognostic study e.g. case series
Level V prognostic study e.g. expert opinion









Article could not be retrieved e.g. not available in electronic or print
archives
Duplicate publication e.g. Similar title, sample size ,and outcome
dataMethods
Search strategy
We conducted a PubMed search on May 26th, 2013 to
identify studies published between January 1st, 2003 and
May 1st, 2013. There is no restriction of language or
country. The search strategy was designed and peer-
reviewed before the beginning of search, which is listed
as follows:
((((thrombosis[Title/Abstract]) OR thromboembolism
[Title/Abstract]) OR embolism [Title/Abstract])) AND
((((risk factor) OR risk factors)) AND ((((total hip arthro-
plasty [Title/Abstract]) OR total hip replacement [Title/
Abstract]) OR total knee arthroplasty [Title/Abstract]) OR
total knee replacement [Title/Abstract])).
Screening has been performed sequentially in three
levels: title, abstract and then full-text as recommended by
the PRISMA Statement criteria [10]. The exclusion cri-
teria is outlined in Table 1. To guarantee the strength of
evidence, only level-I and level-II prognostic studies were
included. Specifically, High-quality prospective studies in
which all patients were enrolled at the same point in their
disease with ≥80% follow-up of enrolled patients are taken
as the level-I, whereas retrospective studies, untreated
controls from a randomized controlled trial and lesser-
quality prospective studies (e.g., patients enrolled at differ-
ent points in their disease or <80% follow-up) are seen as
the level-II. In this way, we assessed the risk of bias of in-
cluded studies mainly based on their study types and
follow-up rates which can be summed up as the “evidence
level”. Also, we assessed all the included papers using the
Newcastle-Ottawa Scale (NOS) of which the detail can
be found at the website: http://www.ohri.ca/programs/
clinical_epidemiology/oxford.htm.Validation
Eligibility assessment was performed independently in
an unblinded standardized manner by 2 reviewers (the
first and the second author). Disagreements between re-
viewers were adjudicated by the senior authors (includ-
ing the third to the sixth author) and ultimately resolved
by consensus.Data abstraction
Data were extracted independently by 2 reviewers from
the included articles. We extracted information on coun-
try, study design, sample size, follow-up time and follow-
up rates. in this process., We also make distinction
between the VTE risk factors for THA and for TKA.
Effect measures such as risk ratio, odds ratio were col-
lected whenever available, as well as the p-values. Corre-
sponding authors of the included articles were contacted
for detailed information or numerical data, if needed. All
of the extractions are based on a preformed sheet.Analysis
A formal meta-analysis can not be done because of the
heterogenous nature among the studies’ type (prospect-
ive and retrospective), follow-up times(from less than
1 week to 3 years) and risk factor specifications. Instead,
we identified all the VTE risk factors reported in at least
one high level study and the number of reporting stud-
ies, then described the direction of significant associa-
tions(defined as p ≤ 0.05 or confidence intervals which
are non-overlapping) of risk factors reported by at least
3 studies. To categorize the included studies in this way
may have limitations because this approach does not
measure the heterogeneity among the studies. However,
Table 3 Number of studies for potential factors
Endpoint VTE*
Total of the endpoint 54






ASA physical status 3 (6%)
Clinical factors
Underlying diagnosis 3 (6%)
Comorbidity (Charlson index) 3 (6%)
Cardiovascular disease 10 (19%)
Respiratory disease 2 (4%)
Neurological disease 1 (2%)
Liver and kidney disease 2 (4%)
Metabolic disease 7 (13%)
Hematological disease 2 (4%)
Endocrine disease 2 (4%)
Malignancy 4 (8%)
Medication (hormone replacement/herbal) 3 (6%)
Laboratory indexes
Preoperative laboratory index 2 (4%)
Postoperative laboratory index 2 (4%)
Health care provider-related factors
Surgery type 12 (22%)
Surgical technic 5 (9%)
Operating time 4 (8%)
Anesthesia 5 (9%)
Bleeding 1 (2%)
Hospital volume 2 (4%)
Insurance type 1 (2%)
Thromboprophylaxes
Chemoprophylaxis 28 (52%)
Initiating and lasting of the prophylaxis 4 (8%)
Mechanical and physical prophylaxis 5 (9%)
*VTE = venous thromboenbolism,which includes DVT(deep vein thrombosis)
and PE (pulmonary embolism).
†Column percentages,not mutually exclusive.
Zhang et al. BMC Musculoskeletal Disorders  (2015) 16:24 Page 3 of 14It does build up a framework of the state across the re-
cent literatures.
As a basic step, the correlations between the risk fac-
tors (or probably the protective factors) and VTE were
classified into three categories: “p ≤ 0.05,+” “p ≤ 0.05,-”
and “p > 0.05”, which means “a significant increased risk
(risk factor)” “a significant decreased risk (protective fac-
tor)” and “with no significant association (controversial
factor)”, respectively.
In the second step, we made comparisons and deter-
mined the direction of significant associations for each
of the factors according to the following rules:
1. 1.A factor reported with “p > 0.05” by all papers
focusing on it is defined as the “controversial factor”;
2. 2.For a factor reported with no fewer than 2 of the 3
categories, e.g. “+”and“-”, as the results, the
proportion number of the first category(“+”) to that
of the second category(“-”) will be compared and the
winner was taken as the final result. In this way, the
factor is defined as the “risk factor” or “protective
factor”.
Therefore we confirmed the VTE risk factors of total
joint arthroplasty.
Ethical compliance
This study was a data-based systematic review and was




We included 54 papers [11-64] from 226 identified titles,
in which about 1,150,000 patients from more than 30
countries and 28 classes of factors were examined. All
the included studies were above level-II and 10 of them
(19%) were level-I. The NOS results were provided in
Table 2. Twenty-eight classes of factors were examined.
The overall frequences of studies and reference numbers
were collected (see Tables 3 and 4). We summarize all
factors examined by at least one study in Tables 4, 5, 6,
7, 8 and 9, in which the factors were classified into five
aspects: demographic factors, clinical factors, labora-




8☆ 14 (26%) [11,14,27,32,38,39,41,43,45,48,50,54,56,63]
7☆ 22 (41%) [15,18,20-23,26,29,35-37,47,49,51,52,55,57-62,64]
6☆ 18 (33%) [12,13,16,17,19,24,25,28,30,31,33,34,40,42,44,46,53]
*N (n%), N = number of studies, n = percentage in the 54 included studies.thromboprophylaxes. The factor examined by at least
three articles are qualified to be determined whether it
is a “risk factor”, a “protective factor” or an “controver-
sial factor” (see Table 10). Factors examined by fewer
than three articles were included but not discussed.
The full search screening procedure and results are
presented in Figure 1. All but one [26] of the 54 papers
Table 4 References of studies for potential factors
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Twelve papers [22,23,26,28-30,35,41,47,52-54] examined
age as a risk factor for VTE. Both THA and TKA have
got themselves reported in no fewer than eight papers.
Of THA, six [22,23,30,35,41,52] reported an increased
risk for older patients. Of TKA patients, three papers
[23,30,35] reported older age as a risk factor for VTE.
A total of four papers [22,23,28,52] took “increased
age” as the potential factor, while other papers investi-
gated some specific cut-off age values such as 60, 70 ,80
and so on. Seniors older than 70 (vs. <70) or 75(vs. <75)
were found with greater VTE risk [33,35]. However, the
above results referring to the specific cut-off age values
were constrained by the number of papers.
Gender
Thirteen papers [18,22,23,26,28-30,35,41,47,52-54] ex-
amined gender as a risk factor for VTE. Both THA and
TKA have got themselves reported in nine papers. Of
THA, two [22,41] reported an increased risk for female
patients while another study [22] found female gender
with decreased VTE risk. Of TKA patients, two papers
[53,54] reported female gender as a risk factor for VTE.
BMI
Six papers [26,28-30,35,54] examined BMI as a risk fac-
tor for VTE. Of THA, one paper [35] among the total of
three papers [30,35,54] reported an increased risk for pa-
tients with higher BMI. Of TKA patients, six papers ex-
amined BMI and one [35] found it a risk factor. The
significant cut-off BMI value of either TKA or THA is
30. Patients with BMI higher than 30 have greater VTE
risks than those with BMI less than 25.
Race
One paper [23] examined race as a risk factor for VTE
for TKA. The black race was found to be a risk factor
while Hispanic race showed no significant difference
when compared to the white race. Hispanic race was
also investigated in the same paper but found with no
significant association with VTE when comparing with
the white race.
ASA physical status
Three papers [35,52,54] examined ASA score as a risk
factor for VTE. Three papers [35,52,54] for THA and
two papers [35,54] for TKA examined this factor. Consist-
ently, none of these papers reported significant association
Table 5 Demographic factors
Risk factors
(demographic factors)
Studies reporting on a risk factor for THA or TKA: total number, number reporting a significant (p≤ .05) increased
(+) or decreased (−) risk, and number with no significant association (p > .05)
THA TKA
N p ≤ .05 p > .05 N p ≤ .05 p > .05
+ - + -
Older age 8 6 0 2 9 3 0 6
Female sex 9 2 1 6 9 2 0 7
Higher BMI* 3 1 0 2 6 1 0 5
Black race (vs. white) - - - - 1 1 0 0
Hispanic race (vs. white) - - - - 1 0 0 1
Higher ASA score† 3 0 0 3 2 0 0 2
*BMI = Body Mass Index.
†The ASA (American Society of Anesthesiologists) score refers to the classification of the physical status of a patient before surgery.
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the three papers used “ASA= 3 or 4” as the potential fac-
tor to compare with “ASA= 1 or 2” but found no signifi-
cant difference.Clinical factors
Underlying diagnosis
Three papers examined underlying diagnoses, e.g. RA or
OA, as risk factors for VTE. One paper [26] described
RA as a risk factor for VTE of TKA. In one paper [46]of
TKA and another paper of THA [47], researchers found
RA a protective factor compared to OA. No significant
association was found when referring to trauma, dyspla-
sia and osteonecrosis.Comorbidity (charlson index)
Three papers examined Charlson comorbidity index as a
risk factor and one paper [54] reported an increased risk
for VTE of TKA patients. Charlson index is widely used
to assess the severity of patients’ comorbidities before
surgery and higher charlson scores indicate worse condi-
tions. Some reseachers [23,47] used different cut-off
values of charlson index, e.g. “1” “3” to compare with “0”
value, while the other one paper [54] used “1 point in-
crease” as the potential risk factor.Cardiovascular disease
Ten papers [18,22,26,29,30,35,47,53,54,62] examined car-
diovascular diseases as a risk factors for VTE. Heart
diseases, cerebrovascular diseases and venous disorders
were included in this class. VTE history was found a sig-
nificant risk factor for THA patients by two [22,47] in
six papers, but with no association with VTE for TKA.
Varicose vein was examined by three papers [26,30,62]
focusing on TKA and turned out to be an controversialfactor. The rest of the cardiovascular factors reported by
less amount of papers were presented in Table 6.
Respiratory disease
Respiratory diseases including pulmonary disease and
sleep apnea were examined by two papers. Pulmonary
disease is found with no association with VTE for either
THA or TKA. One [58] from two papers [35,58] reported
an increased risk of VTE for sleep apnea, applicable to
both THA and TKA.
Neurological disease
One paper [35] examined neurological diseases as risk
factors of VTE for THA and TKA. No significant associ-
ation was found between VTE and both the two kinds of
surgeries. No detail about the neurological disease type
was presented in the paper.
Liver and kidney disease
Two papers [47,61] examined liver and kidney diseases
including chronic kidney disease (CKD) as risk factors of
VTE. One study [61] found CKD3B a risk factor for
THA patients who received enoxaparin as thrombopro-
phylaxis, compared to milder CKDs, e.g. CKD1, CKD2
or CKD3A. In addition, researchers of the above paper
have also took “CKD3B” as a potential risk factor for
THA patients who received desirudin, but found no sig-
nificant association between CKD and VTE rate.
Metabolic disease
Six paper [26,35,37,47,53,59] examined metabolic dis-
eases as a risk factors of VTE for THA and TKA. One
paper [59] for THA and two papers [37,59] for TKA
found metabolic syndrome with increased VTE risk.
Diabetes mellitus was examined by four studies
[26,35,47,53] for both THA and TKA, and showed no
significant association with VTE. Risk directions of
Table 6 Clinical factors
Risk factors (clinical factors) Studies reporting on a risk factor for THA or TKA: total number, number reporting a significant (p ≤ .05)
increased (+) or decreased (−) risk, and number with no significant association (p >. 05)
THA TKA
N p ≤ .05 p > .05 N p ≤ .05 p > .05
+ - + -
Underlying diagnosis
RA (vs. without RA) - - - - 1 1 0 0
RA (vs. OA)* 1 0 1 0 1 0 1 0
Trauma (vs. OA) 1 0 0 1 - - - -
Osteonecrosis (vs. OA) 1 0 0 1 - - - -
Dysplasia (vs. OA) 1 0 0 1 - - - -
Comorbidity
Higher Charlson index† 2 0 0 2 2 1 0 1
Cardiovascular disease 1 1 0 0 - - - -
Stroke 1 0 0 1 1 1 0 0
Heart disease 1 0 0 1 2 0 0 2
CHF/MI‡ 2 1 0 1 1 1 0 0
Coronary artery disease 1 0 0 1 1 0 0 1
Valve disease 1 0 0 1 1 0 0 1
Arrhythmia 2 0 0 2 2 0 0 2
VTE history 6 2 0 4 4 0 0 4
Venous stasis - - - - 1 0 0 1
Varicose vein 2 1 0 1 3 0 0 3
Pulmonary disease 1 0 0 1 1 0 0 1
Sleep apnea 2 1 0 1 2 1 0 1
Neurological disease 1 0 0 1 1 0 0 1
Liver and kidney disease 1 0 0 1 - - - -
CKD3B (vs. CKD1-3A)§ 1 1 0 0 - - - -
Metabolic syndrome 1 1 0 0 2 2 0 0
Diabetes mellitus 4 0 0 4 5 0 0 5
Hypertension 2 0 0 2 3 0 0 3
Dyslipidemia 2 0 0 2 2 0 0 2
Gout - - - - 1 0 0 1
Hematological disease 1 0 0 1 2 1 0 1
Endocrine disease 1 0 0 1 2 0 0 2
Malignancy 4 0 0 4 4 0 0 4
Medication
Hormone replacement 1 0 0 1 3 0 0 3
Herbal therapy - - - - 1 1 0 0
*RA = rheumatoid arthritis, OA = osteoarthritis. †Charlson inex refers to the classification of the comorbidity of a patient before surgery. ‡CHF = congesive heart
failure, MI = Myocardial infarction. §CKD = chronic kidney disease.
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[26] were presented in Table 6. The influences of con-
founders among the above metabolic diseases still re-
main unclear.Hematological disease
Two papers [26,35] examined hematological disease as a
risk factor of VTE. One [26] paper focusing on TKA
found hematological a VTE risk factor. No details about
Table 7 Laboratory indexes
Risk factors (laboratory indexes) Studies reporting on a risk factor for THA or TKA: total number, number reporting a significant
(p ≤ .05) increased (+) or decreased (−) risk, and number with no significant association (p > .05)
THA TKA
N p≤ .05 p > .05 N p ≤ .05 p > .05
+ - + -
Preoperative index
blood glucose ≥ 200 mg/dl 1 1 0 0 1 1 0 0
Resting PaO2 < 75 mmHg - - - - 1 0 0 1
Resting PaCO2 ≥ 45 mmHg - - - - 1 1 0 0
RVSP≥ 35 mmHg* - - - - 1 0 0 1
Postoperative index
Higher platelet counts - - - - 1 1 0 0
Hemoglobin ≥ 10.5 g/dl - - - - 1 1 0 0
AaDO2≥ 34 Torr† - - - - 1 1 0 0
Seroconvertion of IgG-class HIT Antibody‡ - - - - 1 1 0 0
*RVSP = right ventricular systolic pressure, referring to pulmonary hypertension.
†AaDO2 = alveolar-arterial oxygen gradient.
‡HIT = heparin-induced thrombocytopenia, which is a thromboembolic complication that can occur with unfractionated heparin (UFH) or low molecular weight
heparin (LMWH).
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sented in the above paper.
Endocrine disease
Two papers [26,35] examined endocrine disease as a risk
factor of VTE. One paper [35] for THA and two for
TKA [26,35] found no significant association between
endocrine disease and VTE. The specific types of theTable 8 Health care provider-related factors
Risk factors (health care
provider - related
factors)
Studies reporting on a risk factor for THA or
increased (+) or decreased (−) risk, and numb
THA
N p ≤ .05 p > .0
+ -
TKA (vs. THA) 4 2 0 2
THA (vs. resurfacing) 1 1 0 0
Revision (vs. primary) 1 0 0 1
Bilateral (vs. unilateral) 3 1 0 2
Right side (vs. left side) - - - -
Cement (vs. cementless) 2 1 0 1
ROBODOC* (vs. traditional) 1 0 1 0
Longer surgery time 3 1 0 2
General anesthesia 3 0 0 3
Spinal anesthesia - - - -
Bleeding≥ 1280 ml - - - -
Lower hospital volume 1 1 0 0
Insurance type† 1 0 0 1
*ROBODOC is a femoral milling system which excavates the femoral canal precisely
†The comparisons are among private insurance, Medicare and Medicaid of USA.endocrine diseases were not stated except hypothyroid
disorder in one article [26].Malignancy
Four papers [26,35,47,53] examined malignancy as a po-
tential factor of VTE for THA and TKA but none of
them reported a significant association for VTE. NeitherTKA: total number, number reporting a significant (p ≤ .05)
er with no significant association (p > .05)
TKA
5 N p ≤ .05 p > .05
+ -
4 2 0 2
- - - -
2 1 0 1
4 2 0 2
1 0 0 1
3 2 0 1
- - - -
3 1 0 2
3 0 0 3
1 0 0 1
1 1 0 0
2 1 0 1
- - - -
and may reduce intraoperative pulmonary embolism during cementless THA.
Table 9 Thromboprophylaxes
Risk factors (thromboprophylaxes) Studies reporting on a risk factor for THA or TKA: total number, number reporting a
significant (p ≤ .05) increased (+) or decreased (−) risk, and number with no significant
association (p > .05)
THA TKA
N p ≤ .05 p > .05 N p ≤ .05 p > .05
+ - + -
Chemoprophylaxis (vs. no-prophylaxis) 3 0 2 1 3 0 2 1
Enoxaparin (vs. other LMWH) 3 0 1 2 3 0 1 2
Low-dose LMWH (vs. high-dose LMWH) - - - - 1 0 0 1
Preoperative LMWH (vs. Postoperative) 1 0 0 1 2 0 0 2
Oligosaccharides* (vs. LMWH) 2 0 2 0 1 0 0 1
Direct factor-Xa inhibitor (vs. LMWH) 5 0 4 1 5 1 2 2
Direct factor-II inhibitor (vs. LMWH) 2 0 1 1 2 1 0 1
Partial factor-VII inhibitor (vs. LMWH) - - - - 1 0 1 0
NSAIDS (vs. LMWH) 2 0 0 2 1 0 0 1
VKA (vs. NSAIDS) - - - - 1 1 0 0
ACCP-recommended prophylaxis (vs. others ) 1 0 1 0 1 0 1 0
Extended prophylaxis (vs. short)† 1 0 1 0 2 0 2 0
Mechanical prophylaxis (vs. chemoprophylaxis) 1 0 0 1 - - - -
Below-knee stockings (vs. up-knee) - - - - 1 0 0 1
Earlier mobilization 2 0 2 0 3 0 3 0
Weight bearing within 48 h 1 0 0 1 1 0 0 1
*Oligosaccharides include fondaparinux and SR123781A (a synthetic oligosaccharide).
†Extended/short prophylaxis has two kinds of definations:
1. Thromboprophylaxis continued to Day 30 ± 5/Day 10 ± 2;
2. Thromboprophylaxis lasting > 14d/<14d.
Table 10 Factors addressed and confirmed by at least three papers
THA TKA
Risk factors for VTE 1. Older age 1. TKA (vs. THA)
2. Female sex 2. Older age
3. Higher BMI 3. Female sex
4. Bilateral surgery 4. Higher BMI
5. VTE history 5. Bilateral surgery
6. Surgery time > 2 hours 6. Cemented fixation
7. Surgery time > 2 hours
Protective factors for VTE 1. Chemoprophylaxis for VTE* 1. Chemoprophylaxis for VTE*
2. Enoxaparin (vs. other LMWH) 2. Enoxaparin (vs. other LMWH)
3. Direct F-Xa inhibitor (vs. LMWH) 3. Direct F-Xa inhibitor (vs. LMWH)
4. Earlier mobilization
Controversial factors for VTE 1. Diabetes mellitus 1. Diabetes mellitus
2. Malignancy 2. Malignancy
3. General anesthesia 3. General anesthesia




*Compared with no-prophylaxis patients.
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Figure 1 Flow diagram of manuscript search and selection procedure.
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in any papers.
Medication (hormone replacement/herbal)
Three papers [18,26,29] examined medications including
hormone replacement and herbal as risk factors. Hormone
replacement showed no significant association with VTE,
supported by one paper [26] for THA and three [18,26,29]
for TKA.
When regarding to herbal therapy, the only one paper
[26] fount it with an significantly increased risk. The
paper found that the herbal therapy of traditional
Thailand medicine can increase VTE risk for TKA pa-
tients, but it is uncertain whether other kinds of herbal
therapy would increase the VTE risk.
Laboratory indexes
Preoperative laboratory index
Two papers [35,49] examined four kinds of indexes as
risk factors of VTE. One study [35] found blood glucoselevel ≥ 200 mg/dl with an increased VTE risk for both
THA and TKA. This result is not consistent with that
from papers [26,35,47,53] focusing specifically on dia-
betes mellitus.
Resting PaCO2 ≥ 45 mmHg has also proven to be a
VTE risk factor. Resting PaO2 < 75 mmHg and RVSP ≥
35 mmHg were reported by only one paper [49] focusing
on TKA patients and showed no significant association
with VTE.
Postoperative laboratory index
Two papers [28,53] examined four risk factors of VTE
for TKA alone. Each of these factors was reported with
an increased VTE risk. All factors were presented in
Table 7.
Higher platelet counts, hemoglobin ≧ 10.5 g/dl and
AaDO2 ≧ 34 Torr were investigated by one paper [28].
All of the three laboratory indexes were collected 1 day
postoperatively and were found to be VTE risk factors
for TKA patients.
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IgG-class HIT (heparin-induced thrombocytopenia) anti-
body, an indicator of the thromboembolic omplication
that can occur with heparin using. The result of this paper
shows that the seroconvertion of HIT antibody can in-
crease VTE risk of TKA patients. To our knowledge, this
factor has not been studied in THA patients.
Health care provider-related factors
Surgery type
Twelve papers [11-13,18,20,21,26,27,29,30,35,53] exam-
ined surgery types as risk factors of VTE. All factors
reported were presented in Table 8.
TKA is a VTE risk factor, reported by two [18,35] from
four papers [18,30,35,53], compared to THA. Bilateral
arthroplasty surgery were reported with a significant in-
creases VTE risk by one paper [35] for THA and two
[20,35] for TKA.
One paper [41] compared the VTE rates between
THA and THRA (total hip resurfacing arthroplasty) and
found the former with significant increased VTE risk.
Another paper [35] for THA and two [26,35] for TKA
took the revision surgery as a potential VTE risk factor,
compared to primary surgery. Except for the result from
one paper [26] in which the revision surgery turned out
to a risk factor, other results show no significant associ-
ation between the revision surgery and VTE rate.
The surgery sides of the knee, e.g. right side and left
side, were also investigated by one article [26]. The re-
sult shows no significant difference between the two
sides, as expected.
Surgical technique
Five papers [12,13,18,21,29] examined surgical technics,
e.g.fixation and ROBODOC milling system, as risk fac-
tors of VTE. One [18] from two papers [13,18] and two
[18,21] from three papers [18,21,29] reported an in-
creased VTE risk associated with cement fixation, for
THA and TKA patients respectively, while another art-
icle [12] found ROBODOC system a protective factor
compared to traditional technic.
Operating time
Four papers [19,22,35,49] examined surgery time as a
risk factor of VTE for THA or TKA. Only one paer [19]
found longer surgery time (surgery lasting more than
2 hours) with increased VTE risk. Other papers which
used different cut-off value, e.g. 3 hours, found no sig-
nificant association between surgery time and VTE risk.
Anesthesia
Five papers [18,21,29,30,52] examined anesthesia types
as risk factors of VTE. Three papers [18,30,52] for THA
and three for TKA [18,21,30] found general anesthesiawith no significant association for VTE. Spinal anesthesia
was reported with no significant association of TKA by
one paper [29] either.
Bleeding
One paper [28] examined bleeding volume as a risk fac-
tor of VTE for TKA and found it with an increased risk
when more than 1280 ml. The bleeding volume was
defined as the cumulative bleeding volume measured on
the day after the surgery.
Hospital volume
Two papers [23,55] examined lower hospital volume as a
risk factor of VTE for THA and TKA.
The former article [23] which is focusing on TKA,
took the hospitals with the lowest 40% surgical volume
as the “low volume” ones, and those with the highest
20% surgical volume as the “high volume” hospitals, re-
spectively. In this article, higher hospital volume was
found to be VTE risk factor.
The latter article [55] applied a variety of specific cut-
off value of the hospital volume, e.g. 25, 100 and 200.
Significant association between higher volume and in-
creased VTE risk was verified for THA patients, but not
for TKA patients.
Insurance type
One paper [23] examined insurance types, e.g. private
insurance and Medicare/Medicaid, as risk factors of
VTE for THA patients. No significant association was
found in this study. Because this study was conducted in
the United States, the insurance types to be investigated
were based on domestic condition of US, which need to
be mentioned and noticed by the readers.
Thromboprophylaxes
Chemoprophylaxis
28 papers (see Table 4) examined several chemoprophy-
laxis schemes as risk factors of VTE for THA and TKA.
Comparisons and results were listed in Table 9.
Initiating and lasting of the prophylaxis
Two papers [21,30] examined preoperative low molecu-
lar weight heparin (LMWH) compared to postopera-
tively LMWH using. One paper [21] for THA and two
[21,30] for TKA found the initiating time(preoperative
vs. postoperative) with no significant association to VTE.
Extended prophylaxis, which is defined in different way
by two studies [43,57], was compared with short-
duration and reported with a decreased VTE risk.
Mechanical and physical prophylaxis
Five papers [19,24,29,30,52] examined a variety of mech-
anical and physical prophylaxis, e.g. stockings and early
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Earlier mobilization/ambulation was found to signifi-
cantly decrease VTE risk, if achieved at either of the
three time points: 24 hours after surgery, 72 hours after
surgery and before discharge [19,29,30]. No significant
association with VTE was found when regarding to
the following comparisons: mechanical prophylaxis (vs.
chemoprophylaxis) [52], below-knee stockings (vs. up-
knee) [24] and weight bearing within 48 h [30].
Confirmed factors
Risk directions of factors examined in at least three arti-
cles were included in further analysis to be confirmed,
see Table 10. We found six risk VTE factors of THA and
seven risk factors of TKA. Protective factors (four of
THA and four of TKA) and controversial factors (four
of THA and seven of TKA) were also presented in
Table 10. The definition of “confirmed” was described in
the “Analysis” section in this article.
Discussion
We conducted a systematic review on risk factors for
VTE of total joint arthroplasty including THA and TKA
relating to the demographic characteristics of patients,
clinical conditions and so forth. Articles published in re-
cent ten years (2003–2013) were included with data of
more than 1,150,000 patients. We presented all potential
factors studied in at least one paper, and confirmed the
risk directions of all factors examined in at least three
papers by using “risk factor” “protective factor” and
“controversial factor” as conclusions. In this systematic
review of 54 high evidence level papers, six confirmed
VTE risk factors for THA and seven for TKA were
found (see Table 10).
TKA surgery were associated with higher risk of VTE
than that of THA [35,65]. The better postoperative exer-
cising of THA patients could be a reason, but the inner
mechanism has not been studied and is still unclear. We
suggested surgeons and physicians to give closer atten-
tion to TKA patients in monitoring of VTE.
Older age, female gender, higher BMI and bilateral
surgery were found to be VTE risk factors for both THA
and TKA. However, the conclusions about age and BMI
apply only to particular groups of patients. Age > 75 (vs.
age < 75) as well as age > 70 (vs. age < 50) proved to be a
risk factor supported by some papers [30,35,53]. As for
BMI, only those with BMI >30 can be taken as high VTE
risk patients [19,35]. Patients with higher BMI are always
associated bad hemodynamics condition which may
induce the thrombogenesis. Female gender and bilateral
surgery were found to be a risk factor respectively.
The procoagulant function of female hormone and
coagulant-response following the bilateral surgery are
possible explanations [26,29].VTE history seems to be a potential VTE risk factor
with high probability. Surprisingly we found the risk to
be significant only in TKA patients but not in THA
patients. The medical record bias of VTE history may
account for this result. The relationship between VTE
history and VTE after THA/TKA deserves further and
refined research.
Cemented fixation of TKA compared to cementless
was found to be a risk factor for VTE in our study. Con-
sidering the inconsistent results of other studies [66,67]
additional research is necessary before more definite
conclusions can be drawn.
Longer surgery time was found to be a VTE risk factor
for both two kinds of arthroplasty surgeries of low limb.
An operation lasting more than 2 hours may increase
the VTE risk, probably because of multiple surgical ef-
fects on the blood vascular system such as the endothe-
lial injuries and hypercoagulable state [68]. However,
more studies focusing on the relation between operating
time and VTE rate are still needed.
Chemoprophylaxis and mechanical/physical throm-
boprophylaxis which have been widely used already are
widely known “VTE protective factors”. A variety of
comparisons between different thromboprophylaxes have
been included into our systematic review (see Table 9).
Enoxaparin and newly-developed direct Factor Xa in-
hibitors have shown great superiority to LMWH (not
containing and containing enoxaparin respectively). In
addition, earlier mobilization achieved at either of the
three time point (see “Result” section of this article)
was reported with a significant decreased risk for VTE
of TKA, confirmed by several articles [19,29,30]. These
conclusions undoubtedly convince us of the reasonabil-
ity of thromboprophylaxis using.
Several limitations of this systematic review bear fur-
ther comments as follows:
1. Definition inconsistency of “VTE” across the
included papers, e.g. symptomatic or venography-
proven (estimated magnitude of bias: low; effects on
study results: unknown);
2. Limitation on number of available papers for each
potential factor (estimated magnitude of bias:
moderate; effects on study results: difficulty in
assessing particular factors);
3. Selection bias of our review (only level-Iand level-II
evidence were included, therefore some risk factors
examined in lower level studies like case–control
studies were excluded inherently) and publishing
bias favoring statistically significant results
(estimated magnitude of bias: moderate; effects on
study results: neglect of some risk factors);
4. Confounders that have not been adjusted in studies
included, e.g. mutual effects between BMI and
Zhang et al. BMC Musculoskeletal Disorders  (2015) 16:24 Page 12 of 14metabolic diseases, older age and postoperative
immobility (estimated magnitude of bias: moderate;
effects on study results: confounding of risk factors).
In this way, the listed risk factors and protective fac-
tors of this study can only be seen as a lookup table ra-
ther than a final conclusion. Each particular potential
factor need to be examined in further researches.
Doctors are nowadays facing a great challenge in
preventing of VTE for total joint arthroplasty. A stratifi-
cation system of VTE risk and appropriate thrombopro-
phylaxis schemes based on risk classification which suit
the circumstance of each patient are in urgent need.
Common situation is that the risk of VTE decreases
accompanied with the increasing risk of bleeding when
drugs were used, as a result of the dose-effect relation-
ship of most drugs including those newly developed
ones, e.g. direct factor-Xa inhibitor like TAK-442 and
partial factor-VII inhibitor like TB-402 [50,56] Weitz
et al. have conducted chemoprophylaxis based on their
own risk classification systems, and found VTE as well
as bleeding in the “high risk” group treated with high
dose drugs [50,69]. It implicates that the particular dose
of a drug is not enough for some patients in VTE pre-
venting but too strong for others.
Optimal VTE prevention has not been achieved, partly
because of the roughness of the existing risk stratifica-
tion system. Therefore, risk stratification systems need
improvement. However, there is even not any VTE risk
stratification system for total joint arthroplasty, despite
of the “Caprini score” [70] which is not especially for
THA and TKA, to our knowledge. Further research may
clarify the real VTE risk factors and develop a risk
stratification system. In this way, stronger thrombopro-
phylaxes can be given to patients of confirmed VTE
risk, rather than misused to become risk factors for
bleeding.
Conclusions
This systematic review, factors which was found to be
associated with VTE risk of both THA and TKA in-
cluded older age, female sex, higher BMI, bilateral sur-
gery, VTE history and surgery time > 2 hours. Cemented
fixation was found to be a VTE risk factor only for TKA
patients, and “TKA” itself was found to be associated
with higher VTE risk, compared with THA.
Chemoprophylaxis for VTE(vs.no-prophylaxis), enoxa-
parin (vs.other LMWH) and direct F-Xa inhibitor (vs.
LMWH) were found to be VTE protective factors for
both THA and TKA. Earlier mobilization was also a pro-
tective factor for TKA. However, we can not take earlier
mobilization as a VTE protective factor for THA until
sufficient number of papers of high evidence level are
available.By identifying these factors, patients with relatively
higher risk of VTE could be distinguished and therefore
treated more intensively. Further studies are warranted
to brought into more potential VTE factors to provide
robust evidence for this prognostic topic.
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